 Home > Active Ingredient News > Antitumor Therapy > AACR Blockbuster: Combination of high gene amplification and tumor mutational burden as a pan-cancer biomarker in patients receiving tislelizumab

AACR Blockbuster: Combination of high gene amplification and tumor mutational burden as a pan-cancer biomarker in patients receiving tislelizumab

 Last Update: 2022-05-18
 Source: Internet
 Author: User

Tags

data table graph

vitamin skin cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A high tumor mutational burden (TMB-H) was associated with elevated neoantigen expression in tumors and increased response to PD-(L)1 inhibitors

The trial enrolled patients with various solid tumors (pts) and treated them with tislelizumab (NCT02407990)

451 patients were enrolled and treated with different doses of tislelizumab

The results showed that the overall objective response rate of patients was 13.

Table: Clinical outcomes of pts subgroups by TMB and HA status

Further, the trial results were validated in an independent PD-(L)1 inhibitor-treated pan-cancer cohort (n=837)

This study found that the combination of TMB and HA was predictive of clinical benefit with tislelizumab in various solid tumor types

source:

https://#!/10517/presentation/19966

https://#!/10517/presentation/19966 https://#!/10517/presentation/19966

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.